Clinical trial
A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma…
NCT00421512 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00421512 |
|---|---|
| Title | A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients |
| Official title | A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Renal Cell Carcinoma, Kidney Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab and Sunitinib |
| Enrollment | 28 |
| Start date | Mar 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Jan 12, 2007 |
| Last update posted | Nov 11, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: